| The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. RB Kim, MF Fromm, C Wandel, B Leake, AJ Wood, DM Roden, ... The Journal of clinical investigation 101 (2), 289-294, 1998 | 1313 | 1998 |
| Pharmacokinetic interactions with rifampicin: clinical relevance M Niemi, JT Backman, MF Fromm, PJ Neuvonen, KT Kivistö Clinical pharmacokinetics 42, 819-850, 2003 | 812 | 2003 |
| OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine M Cvetkovic, B Leake, MF Fromm, GR Wilkinson, RB Kim Drug metabolism and disposition 27 (8), 866-871, 1999 | 730 | 1999 |
| Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 RK Bhardwaj, H Glaeser, L Becquemont, U Klotz, SK Gupta, MF Fromm Journal of Pharmacology and Experimental Therapeutics 302 (2), 645-650, 2002 | 729 | 2002 |
| Cytochrome P450 2C19 681G> A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary … D Trenk, W Hochholzer, MF Fromm, LE Chialda, A Pahl, CM Valina, ... Journal of the American College of Cardiology 51 (20), 1925-1934, 2008 | 719 | 2008 |
| Importance of P-glycoprotein at blood–tissue barriers MF Fromm Trends in pharmacological sciences 25 (8), 423-429, 2004 | 690 | 2004 |
| Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein RB Kirn, C Wandel, B Leake, M Cvetkovic, MF Fromm, PJ Dempsey, ... Pharmaceutical research 16, 408-414, 1999 | 609 | 1999 |
| Transporters and drug-drug interactions: important determinants of drug disposition and effects J König, F Müller, MF Fromm Pharmacological reviews 65 (3), 944-966, 2013 | 579 | 2013 |
| Inhibition of P-glycoprotein–mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine MF Fromm, RB Kim, CM Stein, GR Wilkinson, DM Roden Circulation 99 (4), 552-557, 1999 | 515 | 1999 |
| P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. MF Fromm International journal of clinical pharmacology and therapeutics 38 (2), 69-74, 2000 | 513 | 2000 |
| The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells M Hitzl, S Drescher, H van der Kuip, E Schäffeler, J Fischer, M Schwab, ... Pharmacogenetics and Genomics 11 (4), 293-298, 2001 | 507 | 2001 |
| High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) M Niemi, E Schaeffeler, T Lang, MF Fromm, M Neuvonen, C Kyrklund, ... Pharmacogenetics and Genomics 14 (7), 429-440, 2004 | 500 | 2004 |
| Pharmacogenomics of human OATP transporters J König, A Seithel, U Gradhand, MF Fromm Naunyn-Schmiedeberg's archives of pharmacology 372, 432-443, 2006 | 445 | 2006 |
| Genetic Polymorphisms of the Human MDR1 Drug Transporter M Schwab, M Eichelbaum, MF Fromm Annual review of pharmacology and toxicology 43 (1), 285-307, 2003 | 424 | 2003 |
| Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis M Schwab, E Schaeffeler, C Marx, MF Fromm, B Kaskas, J Metzler, ... Gastroenterology 124 (1), 26-33, 2003 | 419 | 2003 |
| ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin JE Keskitalo, O Zolk, MF Fromm, KJ Kurkinen, PJ Neuvonen, M Niemi Clinical Pharmacology & Therapeutics 86 (2), 197-203, 2009 | 413 | 2009 |
| Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene A Johne, K Köpke, T Gerloff, I Mai, S Rietbrock, C Meisel, S Hoffmeyer, ... Clinical Pharmacology & Therapeutics 72 (5), 584-594, 2002 | 408 | 2002 |
| Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with … W Hochholzer, D Trenk, MF Fromm, CM Valina, C Stratz, HP Bestehorn, ... Journal of the American College of Cardiology 55 (22), 2427-2434, 2010 | 374 | 2010 |
| Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin MF Fromm, D Busse, HK Kroemer, M Eichelbaum Hepatology 24 (4), 796-801, 1996 | 360 | 1996 |
| The effect of rifampin treatment on intestinal expression of human MRP transporters MF Fromm, HM Kauffmann, P Fritz, O Burk, HK Kroemer, RW Warzok, ... The American journal of pathology 157 (5), 1575-1580, 2000 | 345 | 2000 |
Jörg KönigFriedrich-Alexander-Universität Erlangen, Prof. Dr.Bestätigte E-Mail-Adresse bei fau.de
